Jim Cramer's Stop Trading: 'Amazed' by GW Pharmaceuticals

NEW YORK (TheStreet) -- "I continue to be amazed," by GW Pharmaceuticals (GWPH), TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. 

The company produces the only pure marijuana treatment not laced with other drugs or chemicals, Cramer reasoned. 

He added that the alternative treatments and side effects for epilepsy are "awful," with the exception of GW Pharmaceuticals' treatment. 

It could possibly be used for autism and migraines, he added. The England-based company is working with the U.S. Food and Drug Administration, which likely wants cannabinoid treatments to be legal, Cramer suggested. Eventually, even oxycodone could be replaced with cannabinoid treatments.

Cramer concluded that he's surprised no other company has tried to take over GW Pharmaceuticals, which is higher by 8% today following a price target increase to $147 from $97 at Piper Jaffray. 

-- Written by Bret Kenwell in Petoskey, Mich.

On the Rebound: Detroit Draws Real Estate Investors, Corporate Interest

How to Recession-Proof Your Portfolio With These 5 Dividend Aristocrats

Apple iPhone Ad Sets Tone for Smart Home Products in the Pipeline

Carlos Slim Ends Ties to AT&T With America Movil Stake Buy

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Snap-On, Teekay Shipping, FLIR Systems, GW Pharmaceuticals: 'Mad Money' Lightning Round

Time to Raise Some Cash: Cramer's 'Mad Money' Recap (Tuesday 8/1/17)